ANI Pharmaceuticals: Worthy Of A Position

ANI Pharmaceuticals recently offered up solid FY26 guidance with 15% non-GAAP EPS growth and strong momentum from Cortrophin Gel. ANIP's increasing reliance on Cortrophin Gel, projected to reach 52% of FY26 revenue, is offset by patent protection and a complex formulation. The company's balance sheet remains solid, supporting ongoing investments in rare disease expansion and 10–15 annual generic launches.